CTT PHARMACEUTICAL HOLDINGS, INC.

Operating margin

—

Net margin

—

Return on equity

38.8%

Return on assets

13.7%

Return on capital (ROCE)

—

Liabilities / assets

64.7%

Debt / equity

1.83×

Book value / share

$0.06

Revenue growth (YoY)

—

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Accruals / assets

18.1%high accruals

Piotroski F-Score

4/6mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Director / officer changeFeb 11, 2016
• Prior financials not reliable (restatement)Nov 3, 2015
• Amended charter or bylawsJul 30, 2015
• Director / officer changeJun 16, 2015
• Director / officer changeNov 26, 2014
• Other material eventOct 27, 2014
• Completed an acquisition or disposition · Unregistered equity sale · Director / officer change · Item 5.06Sep 11, 2014
• Unregistered equity saleMay 23, 2014

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.